NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $162 | -23.2% | 20,639 | -13.0% | 0.00% | 0.0% |
| Q1 2023 | $211 | -17.9% | 23,725 | +1.5% | 0.00% | -33.3% |
| Q4 2022 | $257 | -99.9% | 23,375 | -2.1% | 0.00% | -25.0% |
| Q3 2022 | $311,000 | -28.3% | 23,873 | -30.2% | 0.00% | -20.0% |
| Q2 2022 | $434,000 | +2.6% | 34,221 | +134.4% | 0.01% | +150.0% |
| Q4 2021 | $423,000 | -43.8% | 14,599 | -41.8% | 0.00% | -50.0% |
| Q3 2021 | $752,000 | +214.6% | 25,092 | +178.9% | 0.00% | +300.0% |
| Q2 2021 | $239,000 | +2.6% | 8,998 | +20.1% | 0.00% | 0.0% |
| Q1 2021 | $233,000 | – | 7,494 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |